Overview

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

capivasertib